Biogen company profile
Company profile
Biogen has 7,500 employees and is headquartered in Cambridge, United States.
Biogen's sales reach across the United States, Europe, Germany, Asia and other international markets, where it discovers, develops, manufactures and delivers therapies. Its portfolio centres on treatments for multiple sclerosis, including TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and OCREVUS, alongside SPINRAZA for spinal muscular atrophy, SKYCLARYS for Friedreich's Ataxia, QALSODY for amyotrophic lateral sclerosis and LEQEMBI for Alzheimer's disease. The company also sells biosimilars of ENBREL, HUMIRA and REMICADE, anti-CD20 lymphoma and leukemia therapies such as RITUXAN and GAZYVA, and ZURZUVAE for postpartum depression. It works with partners including Eisai, Genentech, UCB and Samsung Bioepis.
In the fiscal year ended December 2025, Biogen reported revenue of USD 9.9 billion, up 2.2% from the previous year, and net income of USD 1.3 billion. The company employs 7,500 people and is headquartered in Cambridge, Massachusetts, where it was founded in 1978.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Country
- United States
- Headquarters
- 225 Binney Street, 02142, Cambridge
- Employees
- 7,500
- Chief executive
- Christopher Viehbacher
- Founded
- 1978
- Fiscal year
- January - December
- Listing
- BIIB · NASDAQ
- Indices
- S&P 500
- Currency
- USD
- ISIN
- US09062X1037
- Website
- biogen.com
Biogen and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| BiogenBIIB | United States | $37.46B | 7,500 | 23.5% | 108.3 |
| Bristol-Myers SquibbBMY | United States | $129.66B | 32,500 | 32.4% | 14.1 |
| PfizerPFE | United States | $164.67B | 75,000 | 29.1% | 41.3 |
| Gilead SciencesGILD | United States | $208.48B | 17,000 | 38.2% | — |
| AmgenAMGN | United States | $251.89B | 31,500 | 34.1% | 27.0 |
| Merck & Co.MRK | United States | $364.26B | 73,000 | 35.2% | 147.8 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
